Biotech Business - June 2, 2022
Asgard Therapeutics granted US patent
Asgard Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted Asgard’s foundational patent related to the method of reprogramming cells towards the dendritic cell fate. The patent provides protection and market exclusivity of products based in the cell reprogramming method until 2038, such as Asgard’s innovative cancer immunotherapies, describes the […]
Financing - November 12, 2021
Asgard Therapeutics raises 6 million EUR
The seed financing was co-led by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden. The funds will be used to further develop off-the-shelf and personalized therapy programs for multiple oncology indications, states the company in a press release. “The support we have received from such a strong syndicate of life science investors, is a strong […]